As a raw food, sashimi can cause foodborne illness because of bacteria and parasites, for example anisakiasis; a disease caused by the accidental ingestion of larval nematodes in the family Anisakidae, primarily Anisakis simplex but also Pseudoterranova decipiens.[2] In addition, incorrectly prepared Fugu fish may contain tetrodotoxin, a potent neurotoxin with no known antidote.
Traditionally, fish that spend at least part of their lives in brackish
or fresh water were considered unsuitable for sashimi because of the
possibility of parasites. For example, salmon, an anadromous fish, is
not traditionally eaten straight out of the river.[citation needed] A study in Seattle, Washington, showed that all wild salmon had roundworm larvae capable of infecting people, while farm-raised salmon did not have any roundworm larvae.[3]
Freezing is often used to kill parasites. According to European Union regulations,[4] freezing fish at −20°C (−4°F) for 24 hours kills parasites. The U.S. Food and Drug Administration (FDA) recommends freezing at −35°C (−31°F) for 15 hours, or at −20°C (−4°F) for 7 days.[5]
While Canada does not federally regulate freezing fish, British Columbia[6] and Alberta[7] voluntarily adhere to guidelines similar to the FDA's.[citation needed] Ontario
attempted to legislate freezing as part of raw food handling
requirements, though this was soon withdrawn due to protests by the
industry that the subtle flavors and texture of raw fish would be
destroyed by freezing. Instead, Ontario has decided to consider
regulations on how raw fish must be handled prior to serving.[8]
Some fish for sashimi are treated with carbon monoxide to keep the flesh red for a longer time in storage. This practice can make spoiled fish appear fresh.[9][10]
The intake of large amounts of certain kinds of fish may affect consumer health due to mercury content.
9 Feb 2015
7 Feb 2015
Medical Obits in DICTIONARY of CANADIAN BIOGRAPHY
loretta.james@utoronto.ca
Fx: 416-978-2611
130 St.George St., Tor.,Ont.M5S 3H1
5 Feb 2015
$6.4-million from Ont.Govt to Ont.Institute for Cancer Research for the "Health Services Research Program".
On World Cancer Day (Feb.4)at Womens' College Hosp the Ont.Minister of Research & Innovation Dr. Reza MORIDI Liberal MPP (Richmond Hill- a Northern Suburb of Toronto) announced the grant.
Dr MORIDI is Editor of USA HEALTH PHYSICS..
MSc(Tehran) M.Tech. & PhD (UK Brunel Univ.-West London,UK)
Dr Moridi was elected a Fellow of UK's Inst.Physics & Inst.Electrical .Engineers
Ontario's DOCTORS" DAY on May 1 was Dr Moridi's idea.
(There was no representative of the OMA Board or 250-staff)
Dr MORIDI is Editor of USA HEALTH PHYSICS..
MSc(Tehran) M.Tech. & PhD (UK Brunel Univ.-West London,UK)
Dr Moridi was elected a Fellow of UK's Inst.Physics & Inst.Electrical .Engineers
Ontario's DOCTORS" DAY on May 1 was Dr Moridi's idea.
(There was no representative of the OMA Board or 250-staff)
30 Jan 2015
London College of Clinical Hypnosis
University validated clinical hypnosis and hypnotherapy training
|
 |
||
|
Introduction to NLP Access Course - £49.50 (60% discount) [2156]
Detailed notes (approx 45 pages) will be provided and software based multimedia tools to automate some NLP techniques will be demonstrated where feasible. You will learn...
*Central London Sat 15 June 2013 10.00 AM to approx 5.00 PM
|
28 Jan 2015
OMA BOARD MEETINGS NOT OPEN TO OMA MEMBERS
The OMA Board meetings are closed to OMA members. In Ontario the public can see the Legislative assembly and Courts at work. Also College pf Phys & Surgeons Tribunals and Council meetings are open to the ;public. HSARB Tribunals are also open to the public. The OMA Board meet in secret. No reason given. Attendance figures are also secret.
23 Jan 2015
J.CLIN.ONCOL.:MRI & MULTIPLE MYELOMA
Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement.
Abstract
PURPOSE: The
aim of International Myeloma Working Group was to develop practical
recommendations for the use of magnetic resonance imaging (MRI) in
multiple myeloma (MM).
METHODS: An
interdisciplinary panel of clinical experts on MM and myeloma bone
disease developed recommendations for the value of MRI based on data
published through March 2014.
RECOMMENDATIONS: MRI
has high sensitivity for the early detection of marrow infiltration by
myeloma cells compared with other radiographic methods. Thus, MRI
detects bone involvement in patients with myeloma much earlier than the
myeloma-related bone destruction, with no radiation exposure. It is the
gold standard for the imaging of axial skeleton, for the evaluation of
painful lesions, and for distinguishing benign versus malignant
osteoporotic vertebral fractures. MRI has the ability to detect spinal
cord or nerve compression and presence of soft tissue masses, and it is
recommended for the workup of solitary bone plasmacytoma. Regarding
smoldering or asymptomatic myeloma, all patients should undergo
whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not
available), and if they have > one focal lesion of a diameter > 5
mm, they should be considered to have symptomatic disease that requires
therapy. In cases of equivocal small lesions, a second MRI should be
performed after 3 to 6 months, and if there is progression on MRI, the
patient should be treated as having symptomatic myeloma. MRI at
diagnosis of symptomatic patients and after treatment (mainly after
autologous stem-cell transplantation) provides prognostic information;
however, to date, this does not change treatment selection.
© 2015 by American Society of Clinical Oncology.PMID
25605835 [PubMed - as supplied by publisher]22 Jan 2015
CAPIO UK Swedbank House 4th Floor 42 New Broad Street London EC2M 1SB Contact: Sarah Gillson, CommunicationCapio is a leading healthcare provider in Europe and supplies services within several medical specialities. Capio´s ambition is to be the healthcare provider that in the best way possible fulfils the demands of our patients, the public healthcare as well as from companies and organisations. That is why we focus on high quality and effective care services with the individual patient's needs and expectations in the centre. Instead of traditional competition, Capio has chosen to collaborate with public healthcare. In close co-operation with healthcare purchasers, principles, methods, models and concepts are developed that create innovative working practices. The Capio Group comprises more than 100 operating units with some 16,000 employees. Capio currently operates in Sweden, Norway, Denmark, Finland, France, the UK, Spain and Switzerland with an annual turnover rate of more than SEK 11, 000 M. Customers are public sector purchases, businesses as well as public and private insurance companies that buy healthcare services. - See more at: http://www.healthcare-today.co.uk/organisation.php?id=3#sthash.0PjBJIit.dpuf
Facebook
Twitter
RSS
0
0
Capio Healthcare UK
Swedbank House4th Floor
42 New Broad Street
London
EC2M 1SB
Contact: Sarah Gillson, Communications Manager
Sub-category: Company - Other
Capio is a leading healthcare provider in Europe and supplies services within several medical specialities. Capio´s ambition is to be the healthcare provider that in the best way possible fulfils the demands of our patients, the public healthcare as well as from companies and organisations. That is why we focus on high quality and effective care services with the individual patient's needs and expectations in the centre.
Instead of traditional competition, Capio has chosen to collaborate with public healthcare. In close co-operation with healthcare purchasers, principles, methods, models and concepts are developed that create innovative working practices.
The Capio Group comprises more than 100 operating units with some 16,000 employees.
Capio currently operates in Sweden, Norway, Denmark, Finland, France, the UK, Spain and Switzerland with an annual turnover rate of more than SEK 11, 000 M.
Customers are public sector purchases, businesses as well as public and private insurance companies that buy healthcare services.
0
0
Capio Healthcare UK
Swedbank House4th Floor
42 New Broad Street
London
EC2M 1SB
Contact: Sarah Gillson, Communications Manager
Sub-category: Company - Other
Capio is a leading healthcare provider in Europe and supplies services within several medical specialities. Capio´s ambition is to be the healthcare provider that in the best way possible fulfils the demands of our patients, the public healthcare as well as from companies and organisations. That is why we focus on high quality and effective care services with the individual patient's needs and expectations in the centre.
Instead of traditional competition, Capio has chosen to collaborate with public healthcare. In close co-operation with healthcare purchasers, principles, methods, models and concepts are developed that create innovative working practices.
The Capio Group comprises more than 100 operating units with some 16,000 employees.
Capio currently operates in Sweden, Norway, Denmark, Finland, France, the UK, Spain and Switzerland with an annual turnover rate of more than SEK 11, 000 M.
Customers are public sector purchases, businesses as well as public and private insurance companies that buy healthcare services.
Subscribe to:
Posts (Atom)